, WRITING COMMITTEE MEMBERS. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, writing on behalf of the 2005 Writing Committee, vol.117, pp.261-295, 2005.
Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised noninferiority trial, Lancet, vol.372, pp.61244-61245, 2008. ,
A new era of prospective real-world safety evaluation primary report of XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System condition-of-approval post-market study), JACC Cardiovasc Interv, vol.4, pp.1298-1309, 2011. ,
Polymer-free drug-coated coronary stents in patients at high bleeding risk, LEADERS FREE Investigators, vol.373, pp.2038-2047, 2015. ,
Is bare-metal stent implantation still justifiable in high bleeding risk patients undergoing percutaneous coronary intervention? A pre-specified analysis from the ZEUS trial, JACC Cardiovasc Interv, vol.9, pp.426-436, 2016. ,
Sinnaeve PR; SENIOR Investigators. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial, Lancet, vol.391, pp.41-50, 2018. ,
Trends in bare-metal stent use in the United States in patients aged >/=65 years (from the CathPCI Registry), Am J Cardiol, vol.118, pp.959-966, 2016. ,
Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions, Circulation, vol.115, pp.2344-2351, 2007. ,
URL : https://hal.archives-ouvertes.fr/hal-02542151
Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium, Circulation, vol.123, pp.2736-2747, 2011. ,
The Academic Research Consortium governance charter, JACC Cardiovasc Interv, vol.4, pp.595-596, 2011. ,
Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary, Eur Heart J, vol.36, pp.2608-2620, 2015. ,
ENDEAVOR II Investigators. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial, Circulation, vol.114, pp.798-806, 2006. ,
Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trial, J Am Coll Cardiol, vol.57, pp.1778-1783, 2011. ,
Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial, JAMA, vol.299, pp.1903-1913, 2008. ,
Dawkins KD; PLATINUM Trial Investigators. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial, J Am Coll Cardiol, vol.57, pp.1700-1708, 2011. ,
Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent: the EVOLVE II Randomized Trial, Circ Cardiovasc Interv, vol.8, p.2372, 2015. ,
Randomized comparison of ridaforolimus-and zotarolimus-eluting coronary stents in patients with coronary artery disease: primary results from the BIONICS Trial (BioNIR Ridaforolimus-Eluting Coronary Stent System in Coronary Stenosis), Circulation, vol.136, pp.1304-1314, 2017. ,
Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial, Lancet, vol.390, pp.1843-1852, 2017. ,
, Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Investigators. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents
, Trial. Eur Heart J, vol.30, pp.2441-2449, 2009.
Comparison of zotarolimus-eluting and everolimus-eluting coronary stents, N Engl J Med, vol.363, pp.136-146, 2010. ,
HOST-ASSURE Investigators. A randomized comparison of platinum chromium-based everolimus-eluting stents versus cobalt chromium-based zotarolimus-eluting stents in all-comers receiving percutaneous coronary intervention: HOST-ASSURE (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & antI-Platelet Regimen), a randomized, controlled, noninferiority trial, J Am Coll Cardiol, vol.63, pp.2805-2816, 2014. ,
SORT OUT III Study Group. Efficacy and safety of zotarolimus-eluting and sirolimuseluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial, Lancet, vol.375, issue.10, pp.60208-60213, 2010. ,
Lö wik MM. Very thin strut biodegradable polymer everolimuseluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial, Lancet, vol.388, issue.16, pp.31920-31921, 2016. ,
,
,
, Drug-eluting or bare-metal stents for coronary artery disease, NORSTENT Investigators, vol.375, pp.1242-1252, 2016.
A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation), J Am Coll Cardiol, vol.60, pp.1340-1348, 2012. ,
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study, Circulation, vol.125, pp.505-513, 2012. ,
Bedside monitoring to adjust antiplatelet therapy for coronary stenting, N Engl J Med, vol.367, pp.2100-2109, 2012. ,
,
, Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators. Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial, Circulation, vol.125, pp.2015-2026, 2012.
Bhatt DL; OPTIMIZE Trial Investigators. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial, JAMA, vol.310, pp.2510-2522, 2013. ,
Massaro JM; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents, N Engl J Med, vol.371, pp.2155-2166, 2014. ,
Second-generation drug-eluting stent implantation followed by 6-versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial, J Am Coll Cardiol, vol.64, pp.2086-2097, 2014. ,
PRECISE-DAPT Study Investigators. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials, Lancet, vol.389, issue.17, pp.30397-30402, 2017. ,
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drugeluting stent: a multicentre, open-label, randomised superiority trial, Lancet, vol.392, pp.940-949, 2018. ,
SMART-DATE Investigators. 6-Month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial, Lancet, vol.391, issue.18, pp.30493-30501, 2018. ,
Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates, J Am Coll Cardiol, vol.65, pp.805-815, 2015. ,
Development and external validation of a post-discharge bleeding risk score in patients with acute coronary syndrome: the BleeMACS score, Int J Cardiol, vol.254, pp.10-15, 2018. ,
Primary non-variceal upper gastrointestinal bleeding in NSAID and low-dose aspirin users: development and validation of risk scores for either medication in two large Dutch cohorts, J Gastroenterol, vol.49, pp.245-253, 2014. ,
Coronary thrombosis and major bleeding after PCI with drugeluting stents: risk scores from PARIS, J Am Coll Cardiol, vol.67, pp.2224-2234, 2016. ,
Steg PG; REACH Investigators. Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis, Eur Heart J, vol.31, pp.1257-1265, 2010. ,
,
, ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)
, Eur Heart J, vol.39, pp.213-260, 2018.
Mauri L; DAPT Study Investigators. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention, JAMA, vol.315, pp.1735-1749, 2016. ,
Rivaroxaban with or without aspirin in stable cardiovascular disease, N Engl J Med, vol.377, pp.1319-1330, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01892329
Coronary revascularization in the community: a population-based study, J Am Coll Cardiol, vol.50, pp.1223-1229, 1990. ,
Trends in U.S. cardiovascular care: 2016 report from 4 ACC national cardiovascular data registries, J Am Coll Cardiol, vol.69, pp.1427-1450, 2017. ,
New York State Angioplasty Registry. Comparison of outcomes of percutaneous coronary interventions in patients of three age groups (<60, 60 to 80, and >80 years) (from the New York State Angioplasty Registry), Am J Cardiol, vol.98, pp.1334-1339, 2006. ,
elderly patients: a predefined sub-study of the LEADERS FREE trial, Int J Cardiol, vol.243, pp.110-115, 2017. ,
Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score, Circulation, vol.119, pp.1873-1882, 2009. ,
A risk score to predict bleeding in patients with acute coronary syndromes, J Am Coll Cardiol, vol.55, pp.2556-2566, 2010. ,
In-hospital major bleeding during STelevation and non-ST-elevation myocardial infarction care: derivation and validation of a model from the ACTION Registry(R)-GWTG, Am J Cardiol, vol.107, pp.1136-1143, 2011. ,
An updated bleeding model to predict the risk of post-procedure bleeding among patients undergoing percutaneous coronary intervention: a report using an expanded bleeding definition from the National Cardiovascular Data Registry CathPCI Registry, JACC Cardiovasc Interv, vol.6, pp.897-904, 2013. ,
Personalising the decision for prolonged dual antiplatelet therapy: development, validation and potential impact of prognostic models for cardiovascular events and bleeding in myocardial infarction survivors, Eur Heart J, vol.38, pp.1048-1055, 2017. ,
Shortterm versus long-term dual antiplatelet therapy after drug-eluting stent implantation in elderly patients: a meta-analysis of individual participant data from 6 randomized trials, JACC Cardiovasc Interv, vol.11, pp.435-443, 2018. ,
Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions, Circ Cardiovasc Interv, vol.7, pp.113-124, 2014. ,
Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention, Circulation, vol.138, pp.527-536, 2018. ,
Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial, Lancet, vol.381, pp.1107-1115, 2013. ,
Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE Trial, J Am Coll Cardiol, vol.65, pp.1619-1629, 2015. ,
Prevention of bleeding in patients with atrial fibrillation undergoing PCI, N Engl J Med, vol.375, pp.2423-2434, 2016. ,
Hohnloser SH; RE-DUAL PCI Steering Committee and Investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation, N Engl J Med, vol.377, pp.1513-1524, 2017. ,
Validated contemporary risk model of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the National Cardiovascular Data Registry Cath-PCI Registry, J Am Heart Assoc, vol.3, p.1380, 2014. ,
Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) substudy, JACC Cardiovasc Interv, vol.2, pp.748-757, 2009. ,
Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial, JACC Cardiovasc Interv, vol.4, pp.1011-1019, 2011. ,
EVENT Investigators. In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry, JACC Cardiovasc Interv, vol.2, pp.37-45, 2009. ,
Incidence, patterns, and impact of dual antiplatelet therapy cessation among patients with and without chronic kidney disease undergoing percutaneous coronary intervention: results from the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients), Circ Cardiovasc Interv, vol.11, p.6144, 2018. ,
Prevalence and impact of high platelet reactivity in chronic kidney disease: results from the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents registry, Circ Cardiovasc Interv, vol.8, p.1683, 2015. ,
The impact of anemia on long-term clinical outcome in patients undergoing revascularization with the unrestricted use of drug-eluting stents, Circ Cardiovasc Interv, vol.5, pp.202-210, 2012. ,
Anemia in patients with acute coronary syndromes treated with prasugrel or ticagrelor: insights from the RENAMI registry, Thromb Res, vol.167, pp.142-148, 2018. ,
Meta-analysis of the prognostic impact of anemia in patients undergoing percutaneous coronary intervention, Am J Cardiol, vol.118, pp.610-620, 2016. ,
Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding, N Engl J Med, vol.352, pp.238-244, 2005. ,
Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial, Ann Intern Med, vol.152, pp.1-9, 2010. ,
Transfusion strategies for acute upper gastrointestinal bleeding, N Engl J Med, vol.368, pp.11-21, 2013. ,
The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: a clinical conundrum, Eur Heart J, vol.38, pp.3488-3492, 2017. ,
Impact of chronic thrombocytopenia on in-hospital outcomes after percutaneous coronary intervention, JACC Cardiovasc Interv, vol.11, pp.1862-1868, 2018. ,
Impact of baseline thrombocytopenia on bleeding and mortality after percutaneous, Am J Cardiol, vol.121, pp.1304-1314, 2018. ,
Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial, Am Heart J, vol.161, pp.391-396, 2011. ,
Prevention and treatment of atherosclerosis in haemophilia: how to balance risk of bleeding with risk of ischaemic events, Eur J Haematol, vol.94, issue.77, pp.23-29, 2015. ,
Advances in the diagnosis and treatment of von Willebrand disease, Blood, vol.130, pp.2386-2391, 2017. ,
Atherothrombosis in von Willebrand disease: an analysis of the literature and implications for clinical management, Semin Thromb Hemost, vol.38, pp.185-199, 2012. ,
Coronary angiography with or without percutaneous coronary intervention in patients with hemophilia: systematic review, Catheter Cardiovasc Interv, vol.92, pp.1-15, 2018. ,
The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease, Blood, vol.123, pp.4037-4044, 2014. ,
Percutaneous coronary intervention in patients with end-stage liver disease, Am J Cardiol, vol.117, pp.1729-1734, 2016. ,
The pathophysiology of thrombocytopenia in chronic liver disease, Hepat Med, vol.8, pp.39-50, 2016. ,
Coronary artery stents and antiplatelet therapy in patients with cirrhosis, J Clin Gastroenterol, vol.46, pp.339-344, 2012. ,
Role of cardiac catheterization and percutaneous coronary intervention in the preoperative assessment and management of patients before orthotopic liver transplantation, Liver Transpl, vol.20, pp.664-672, 2014. ,
Temporal trends, predictors, and outcomes of in-hospital gastrointestinal bleeding associated with percutaneous coronary intervention, Am J Cardiol, vol.118, pp.1150-1157, 2016. ,
Patients with cirrhosis who have coronary artery disease treated with cardiac stents have high rates of gastrointestinal bleeding ,
, Aliment Pharmacol Ther, vol.46, pp.183-192, 2017.
Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients, J Thromb Haemost, vol.3, pp.692-694, 2005. ,
Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH, J Thromb Haemost, vol.13, pp.2119-2126, 2015. ,
Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment, Hepatology, vol.66, pp.1556-1569, 2017. ,
A model to predict survival in patients with end-stage liver disease, Hepatology, vol.33, pp.464-470, 2001. ,
Surgery and portal hypertension, Major Probl Clin Surg, vol.1, pp.1-85, 1964. ,
Transection of the oesophagus for bleeding oesophageal varices, Br J Surg, vol.60, pp.646-649, 1973. ,
Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States, 2018. ,
, Eur Heart J
Incidence, predictors, and prognostic implications of hospitalization for late bleeding after percutaneous coronary intervention for patients older than 65 years, Circ Cardiovasc Interv, vol.3, pp.140-147, 2010. ,
Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome, Eur Heart J, vol.37, pp.412-422, 2016. ,
Population trends in percutaneous coronary intervention: 20-year results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry), J Am Coll Cardiol, vol.61, pp.1222-1230, 2013. ,
In-hospital outcomes of percutaneous coronary intervention in America's safety net: insights from the NCDR Cath-PCI Registry, JACC Cardiovasc Interv, vol.10, pp.1475-1485, 2017. ,
Yusuf S; CURRENT-OASIS 7 trial investigators. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial, Lancet, vol.376, issue.10, pp.61088-61092, 2010. ,
Ticagrelor versus clopidogrel in patients with acute coronary syndromes, N Engl J Med, vol.361, pp.1045-1057, 2009. ,
Efient public assessment report: product information, 2009. ,
Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack, Circulation, vol.125, pp.2914-2921, 2012. ,
Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events TSC and Investigators. Efficacy and safety of vorapaxar in patients with prior ischemic stroke, Stroke, vol.44, pp.691-698, 2013. ,
,
, Clopidogrel with aspirin in acute minor stroke or transient ischemic attack, CHANCE Investigators, vol.369, pp.11-19, 2013.
SOCRATES Steering Committee and Investigators. Ticagrelor versus aspirin in acute stroke or transient ischemic attack, N Engl J Med, vol.375, pp.35-43, 2016. ,
Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA, Neurological Emergencies Treatment Trials Network, and the POINT Investigators, vol.379, pp.215-225, 2018. ,
Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial, Lancet, vol.364, issue.04, pp.16721-16725, 2004. ,
,
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke, N Engl J Med, vol.359, pp.1238-1251, 2008. ,
Effects of clopidogrel added to aspirin in patients with recent lacunar stroke, N Engl J Med, vol.367, pp.817-825, 2012. ,
,
, Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the, American Heart Association/American Stroke Association. Stroke, vol.49, pp.46-110, 2018.
American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the, American Heart Association/American Stroke Association. Stroke, vol.45, pp.2160-2236, 2014. ,
American Heart Association Stroke Council. Management of brain arteriovenous malformations: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association, Stroke, vol.48, pp.200-224, 2017. ,
Untreated brain arteriovenous malformation: patient-level meta-analysis of hemorrhage predictors, Neurology, vol.83, pp.590-597, 2014. ,
Moskowitz AJ; International ARUBA Investigators. Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial, Lancet, vol.383, pp.614-621, 2014. ,
Management of antiplatelet therapy in patients with coronary artery disease requiring cardiac and noncardiac surgery, Circulation, vol.128, pp.2785-2798, 2013. ,
Use of antiplatelet therapy/DAPT for post-PCI patients undergoing noncardiac surgery, J Am Coll Cardiol, vol.69, pp.1861-1870, 2017. ,
POISE-2 Investigators. Aspirin in patients undergoing noncardiac surgery, N Engl J Med, vol.370, pp.1494-1503, 2014. ,
,
, Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA), ESC/ESA guidelines on non-cardiac surgery: cardiovascular assessment and management: the, vol.35, pp.2383-2431, 2014.
ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, J Am Coll Cardiol, vol.68, pp.1082-1115, 2016. ,
, Italian Society of Interventional Cardiology (SICI-GISE
, Italian Society for the Study of Haemostasis and Thrombosis (SISET)
, Italian Society of Anesthesia and Intensive Care Medicine (SIAARTI
, Italian Society of Surgery (SIC
, Italian Society for Cardiac Surgery (SICCH
, Italian Society of Vascular and Endovascular Surgery
, Italian Society of Urology (SIU
, Italian Orthopaedic Society (SIOT
, Italian Society of Thoracic Surgeons (SICT
, Italian Federation of Scientific Societies of Digestive System Diseases (FISMAD)
, Italian Society of Digestive Endoscopy (SIED
, Italian Association of Hospital Gastroenterology and Digestive Endoscopy
, Italian Association of Gastroenterology and Digestive Endoscopy
, Italian Society of Maxillofacial Surgery (SICMF
, Italian Society of Reconstructive Plastic Surgery and Aesthetics (SICPRE
, Italian Society of Gynecology and Obstetrics (SIGO
, Italian Society of Neurosurgery
, Italian Association of Hospital Pulmonologist (AIPO
, Italian Society of Periodontology (SIdP
, Italian Society of Ophthalmology (SOI
, Italian Association of Hospital Otorhinolaryngologist (AOOI
, A multidisciplinary approach on the perioperative antithrombotic management of patients with coronary stents undergoing surgery: surgery after stenting 2, JACC Cardiovasc Interv, vol.11, pp.417-434, 2018.
Management of antiplatelet therapy in patients undergoing elective invasive procedures: proposals from the French Working Group on Perioperative Hemostasis (GIHP) and the French Study Group on Thrombosis and Hemostasis (GFHT): in collaboration with the French Society for Anesthesia and Intensive Care (SFAR), Arch Cardiovasc Dis, vol.111, pp.210-223, 2018. ,
Perioperative and periprocedural management of antithrombotic therapy: consensus document of SEC, Rev Esp Cardiol (Engl Ed), vol.71, pp.553-564, 2018. ,
Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study, Lancet, vol.369, pp.60314-60320, 2007. ,
Mitsudo K; j-Cypher Registry Investigators. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation, Circulation, vol.119, pp.987-995, 2009. ,
Bertges DJ; Vascular Quality Initiative. Regional variation in postoperative myocardial infarction in patients undergoing vascular surgery in the United States, Ann Vasc Surg, vol.40, pp.63-73, 2017. ,
Cardiorenal safety of OTC analgesics, J Cardiovasc Pharmacol Ther, vol.23, pp.103-118, 2018. ,
Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: a view from the ARAMIS database: Arthritis, Rheumatism, and Aging Medical Information System, Am J Ther, vol.7, pp.115-121, 2000. ,
Mechanisms of damage to the gastrointestinal tract from nonsteroidal antiinflammatory drugs, Gastroenterology, vol.154, pp.500-514, 2018. ,
Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAIDrelated ulcer complications, Am J Gastroenterol, vol.104, pp.728-738, 2009. ,
,
Risk of upper gastrointestinal bleeding from different drug combinations, Gastroenterology, vol.147, pp.784-792, 2014. ,
Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial, Lancet, vol.389, issue.17, pp.30981-30990, 2017. ,
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial: Celecoxib Long-term Arthritis Safety Study, JAMA, vol.284, pp.1247-1255, 2000. ,
Agreement between 35 published frailty scores in the general population, Am J Epidemiol, vol.186, pp.420-434, 2017. ,
The association of frailty with in-hospital bleeding among older adults with acute myocardial infarction: insights from the ACTION Registry, JACC Cardiovasc Interv, vol.11, pp.2287-2296, 2018. ,
Incidence and predictors of bleeding complications after percutaneous coronary intervention, J Cardiol, vol.69, pp.272-279, 2017. ,
Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study, Circ J, vol.78, pp.1684-1692, 2014. ,
An international comparison of patients undergoing percutaneous coronary intervention: a collaborative study of the National Cardiovascular Data Registry (NCDR) and Japan Cardiovascular Database-Keio interhospital Cardiovascular Studies (JCD-KiCS), Am Heart J, vol.170, pp.1077-1085, 2015. ,
Racial differences in ischaemia/bleeding risk trade-off during anti-platelet therapy: individual patient level landmark meta-analysis from seven RCTs, Thromb Haemost, vol.119, pp.149-162, 2019. ,
Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention, JACC Cardiovasc Interv, vol.4, pp.191-197, 2011. ,
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis, Circulation, vol.122, pp.2131-2141, 2010. ,
Antman EM; TRITON-TIMI 38 Investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for STelevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial, Lancet, vol.373, issue.09, pp.60441-60445, 2009. ,
Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study, Lancet, vol.382, issue.13, pp.61720-61721, 2013. ,